Detailed Narrative
Robust Q1 FY26 Financial Performance
Thyrocare reported a strong Q1 FY26 with consolidated revenue growing 23% year-on-year to ₹193 crores. This growth was primarily organic, contributing 21%, with the remaining 2% from inorganic sources. Standalone normalized EBITDA margin expanded by 354 basis points to 35%, driven by better gross margins and operating leverage. Consolidated normalized EBITDA increased 42% YoY to ₹63.35 crores, and Profit After Tax (PAT) surged 62% YoY to ₹38.06 crores.
Accelerated Franchisee and Network Expansion
The active quarterly franchisee count reached over 9,500 in Q1 FY26, a significant increase from 8,145 in Q1 FY25. Management aims for 1,200 to 1,500 net franchisee additions in FY26. The company expanded its geographical footprint by opening new partner labs in Roorkee, Kashmir, and a new regional lab in Bhagalpur. The strategy focuses on onboarding existing diagnostic centers to the Thyrocare ecosystem, ensuring faster contribution to the topline.
Operational Excellence and Quality Focus
Thyrocare achieved 100% NABL accreditation across its national laboratory chain, a significant milestone. The company has set a target for six sigma-level quality processes, aiming to reduce complaints per million from 4 to below 3.4. Turnaround time (TAT) improved, with reports released within 3.35 hours of sample arrival at the lab on average in Q1 FY26, demonstrating efficiency and precision.
Strategic Integrations and Product Portfolio Expansion
The company successfully integrated the Polo and Vimta networks and is live with ECG at home services through the acquired Think Health. New brands like Jaanch and Her Check were launched, targeting lifestyle challenges and specific health needs. The test menu is approximately 1,000 tests, with recent additions including histopathology, new HPLC equipment, and a first foray into Coagulation, along with BioFire PCR platforms.
Strong Growth in Partnership Business
The partnerships business demonstrated robust growth of 36% year-on-year, or 29% excluding API. The API Pharmacy Diagnostic business grew by 52% year-on-year, while the Radiology business grew by 6%. Management highlighted the success of cross-selling diagnostics on the PharmEasy platform, which has returned to a strong growth track of 30%-40%.
Commitment to Reinvestment for Growth
Management reiterated its strategy to reinvest profits back into the business, maintaining a guidance of 30% EBITDA margin, even as current margins are higher. The focus is on deploying capital for faster business expansion, particularly through strategic acquisitions, leveraging the successful integration of recent acquisitions like Vimta and Polo. The company remains debt-free with high operating cash flow, preferring CAPEX over reagent rental models for cost efficiency.